



June 2015

As you may be aware, a post on a social media site about Bravecto started circulating in the past day. As a responsible animal health company, we take every report seriously and investigate thoroughly. The health and well-being of animals is our first and foremost priority. Please know we are working diligently to address the situation and want to make sure you are aware of the facts and the actions being taken.

While we have no information related to this post in our pharmacovigilance database, which means it has not been reported to Merck Animal Health, we are taking proactive measures to reach the pet owner and the attending veterinarian. Without any means to contact the pet owners directly, we have reached out via email and phone to the organization that hosts the Facebook page to try to secure contact information. We also are looking into other means of reaching the pet owners.

In the meantime, we want to reiterate the safety of Bravecto and provide you with some talking points, if needed, to respond to pet owner inquiries. As always, you can also reach out to your Merck Animal Health sales representative or our technical services team to ask questions or request additional information.

- Following rigorous testing and submission of extensive study data, the FDA deemed Bravecto, when used according to label, safe and effective.
 - Peer-review published studies describing the safety of BRAVECTO are readily available at: <http://www.parasitesandvectors.com/series/BRAVECTO>.
- In addition, the safety data for BRAVECTO have been thoroughly evaluated by the EMA (European Medicines Agency) and VDD (Veterinary Drugs Directorate — Canada's regulatory agency), and the product was deemed safe for use as directed by those regulatory authorities.
- Bravecto was shown to be well-tolerated in studies. No dogs experienced serious adverse events.
 - Commonly observed adverse reactions in clinical trials (1.6% of treated dogs) were mild and transient gastrointestinal effects such as diarrhea, vomiting, inappetence and drooling.

Our commitment is to the health and well-being of pets, and addressing this situation is a priority. If additional information becomes available, we will share that with you. Again, please don't hesitate to reach out to our team for additional support.

Regards,

A handwritten signature in black ink, appearing to read "Scott Bormann".

Scott Bormann
Vice President, N.A. Commercial Operations

A handwritten signature in black ink, appearing to read "Jim Heinle".

Jim Heinle
Business Unit Head, Companion Animal

IMPORTANT SAFETY INFORMATION: The most common adverse reactions recorded in clinical trials were vomiting, decreased appetite, diarrhea, lethargy, polydipsia, and flatulence. Bravecto has not been shown to be effective for 12-weeks' duration in puppies less than 6 months of age. Bravecto is not effective against lone star ticks beyond 8 weeks after dosing. For full prescribing information, click [here](#).